Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $6.3 million.

  • Regenxbio's Change in Receivables rose 78873.24% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year increase of 7910.18%. This contributed to the annual value of -$9.7 million for FY2024, which is 14668.36% down from last year.
  • Latest data reveals that Regenxbio reported Change in Receivables of $6.3 million as of Q3 2025, which was up 78873.24% from $2.4 million recorded in Q2 2025.
  • Regenxbio's 5-year Change in Receivables high stood at $10.7 million for Q2 2022, and its period low was -$22.0 million during Q4 2021.
  • For the 5-year period, Regenxbio's Change in Receivables averaged around -$1.3 million, with its median value being -$1.6 million (2025).
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 25160.69% in 2022, then soared by 78873.24% in 2025.
  • Over the past 5 years, Regenxbio's Change in Receivables (Quarter) stood at -$22.0 million in 2021, then soared by 77.99% to -$4.8 million in 2022, then soared by 30.45% to -$3.4 million in 2023, then plummeted by 141.41% to -$8.1 million in 2024, then skyrocketed by 177.59% to $6.3 million in 2025.
  • Its Change in Receivables was $6.3 million in Q3 2025, compared to $2.4 million in Q2 2025 and -$1.6 million in Q1 2025.